| Literature DB >> 35889965 |
Jiun-Liang Chen1, Tsung-Yu Huang2,3,4, Wei-Bin Hsu5, Chiang-Wen Lee6,7,8, Yao-Chang Chiang6, Pey-Jium Chang9,10, Kuo-Ti Peng1,2.
Abstract
Periprosthetic joint infection (PJI) is a troublesome clinical issue in total joint arthroplasty (TJA). Although methicillin-resistant Staphylococcus aureus (MRSA) is considered to be the most serious pathogen in PJIs, little is known about the genotypic and phenotypic characteristics of MRSA clones isolated from PJI patients. A total of 36 MRSA isolates from PJI patients were collected at the Chang-Gung Memorial Hospital in Taiwan from May 2016 to October 2019. All MRSA isolates were subjected to genome typing. The prevalence of Panton-Valentine leucocidin (PVL), the antibiotic susceptibility profile, and the biofilm formation ability were compared among different MRSA genogroups. Additionally, demographics and clinical manifestations of patients infected with different MRSA genogroups were investigated. Eight sequence types (STs) were identified among 36 isolated from PJIs. According to the incidence of MRSA genotypes in PJIs, in this study, we divided them into four groups, including ST8 (n = 10), ST59 (n = 8), ST239 (n = 11), and other STs (n = 7). For the antibiotic susceptibility testing, we found that all MRSA isolates in the ST239 group were highly resistant to ciprofloxacin, gentamicin trimethoprim-sulfamethoxazole, and levofloxacin. Additionally, ST239 MRSA also had a higher ability to form biofilm than other groups. Importantly, patients with ST239 infection typically had a fever and exhibited higher levels of inflammatory markers, including C-reactive protein (CRP) and white blood cell count (WBC). Epidemiological investigations revealed that knee PJIs were mainly attributed to infection with ST59 MRSA and increasing trends for infection with ST8 and other ST types of MRSAs in PJI patients were observed from 2016 to 2019. The identification of MRSA genotypes in PJIs may be helpful for the management of PJIs.Entities:
Keywords: genotypes; methicillin-resistant Staphylococcus aureus; periprosthetic joint infection; phenotypes
Year: 2022 PMID: 35889965 PMCID: PMC9316792 DOI: 10.3390/pathogens11070719
Source DB: PubMed Journal: Pathogens ISSN: 2076-0817
Demographics of patients with MRSA PJIs.
| Characteristic | PJIs ( |
|---|---|
| Sex | |
| Female | 16 (44%) |
| Male | 20 (56%) |
| Age (year) | |
| Mean ± SD | 64 ± 18 |
| Range | 26–98 |
| Surgical sites | |
| Elbow | 1 (3%) |
| Hip | 29 (81%) |
| Knee | 6 (17%) |
| Underlying diseases | |
| CHC | 17 (47%) |
| CKD | 3 (8%) |
| DM | 9 (25%) |
| Gout | 3 (8%) |
| Cancer | 2 (6%) |
Abbreviation: MRSA—methicillin-resistant Staphylococcus aureus; PJIs—periprosthetic joint infections; CHC—chronic hepatitis and cirrhosis; CKD—chronic kidney disease; DM—diabetes mellitus.
Molecular genotyping analysis of MRSA isolates from PJIs (n = 36).
| SCC | MLST, No. (%) | PVL Positive, No. (%) | ||||||
|---|---|---|---|---|---|---|---|---|
| II | 1 (3%) | ST5 | 2 (6%) | t002 | 2 (6%) | 22 (61%) | ||
| III | 13 (36%) | ST7 | 1 (3%) | t008 | 9 (25%) | |||
| IV | 13 (36%) | ST8 | 10 (28%) | t015 | 2 (6%) | |||
| V | 9 (25%) | ST45 | 1 (3%) | t034 | 1 (3%) | |||
| ST59 | 8 (22%) | t037 | 11 (31%) | |||||
| ST239 | 11 (31%) | t091 | 1 (3%) | |||||
| ST508 | 2 (6%) | t437 | 8 (22%) | |||||
| ST1232 | 1 (3%) | t441 | 1 (3%) | |||||
| t1081 | 1 (3%) | |||||||
Abbreviations: MRSA—methicillin-resistant Staphylococcus aureus; PJIs—periprosthetic joint infections; SCCmec—staphylococcal cassette chromosome mec; MLST—multilocus sequence typing; ST—sequence type; spa—staphylococcal protein A; PVL—Panton–Valentine leucocidin.
Genogroups of MRSA isolates in PJIs (n = 36).
| Genogroups | Lineages | MRSA Isolates, % |
|---|---|---|
| ST8 ( | t008-SCC | 6 (17%) |
| t008-SCC | 1 (3%) | |
| t008-SCC | 2 (6%) | |
| t441-SCC | 1 (3%) | |
| ST59 ( | t437-SCC | 1 (3%) |
| t437-SCC | 2 (6%) | |
| t437-SCC | 5 (14%) | |
| ST239 ( | t037-SCC | 5 (14%) |
| t037-SCC | 6 (17%) | |
| Others ( | ||
| ST5 | t002-SCC | 1 (3%) |
| t002-SCC | 1 (3%) | |
| ST7 | t091-SCC | 1 (3%) |
| ST45 | t1081-SCC | 1 (3%) |
| ST508 | t015-SCC | 2 (6%) |
| ST1232 | t034-SCC | 1 (3%) |
Abbreviations: MRSA—methicillin-resistant Staphylococcus aureus; PJI—periprosthetic joint infections; ST—sequence type; SCCmec—staphylococcal cassette chromosome mec; PVL—Panton–Valentine leucocidin.
Association between antibiotic resistance profiles and genotypes of MRSA isolates from PJIs (n = 36).
| Antibiotic | MIC a (µg/mL) | Total Strains ( | MRSA Genogroups (Resistance, %) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ST8 | ST59 | ST239 | ST5 | ST7 | ST45 | ST508 | ST1232 | |||
| Ciprofloxacin | ≥4 | 24 (67%) | 8 (80) | 2 (25) | 11 (100) | 2 (100) | 0 | 1 (100) | 0 | 0 |
| Gentamicin | ≥16 | 17 (44%) | 1 (10) | 3 (38) | 11(100) | 2 (100) | 0 | 0 | 0 | 0 |
| TMP-SMX | ≥4 | 11 (31%) | 0 | 0 | 11 (100) | 0 | 0 | 0 | 0 | 0 |
| Fusidic acid | ≥1 | 5 (14%) | 1 (10) | 2 (25) | 1 (9) | 0 | 1 (100) | 0 | 0 | 0 |
| Rifampicin | ≥4 | 2 (6%) | 0 | 0 | 0 | 2 (100) | 0 | 0 | 0 | 0 |
| Vancomycin | ≥2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
a MIC values determined by E-test. Abbreviations: MLST—multilocus sequence typing; MRSA—methicillin-resistant Staphylococcus aureus; MIC—minimum inhibitoryconcentration; ST—sequence type; PJIs—periprosthetic joint infections; TMP-SMX—trimethoprim-sulfamethoxazole.
The MIC of values of each strain for all antibiotics.
| MLST | Strain | MICof Antibiotics (μg/mL) | |||||
|---|---|---|---|---|---|---|---|
| Ciprofloxacin | Gentamicin | TMP-SMX | Fusidic Acid | Rifampicin | Vancomycin | ||
| ST8 | Sta-25 | 12 | 12 | 0.064 | 3 | 0.008 | 1.5 |
| Sta-30 | 12 | 0.5 | 0.064 | 0.064 | 0.006 | 1 | |
| Sta-581 | 32 | 0.38 | 0.064 | 0.047 | 0.006 | 0.5 | |
| Sta-582 | 0.19 | 0.38 | 0.047 | 0.047 | 0.006 | 0.5 | |
| Sta-596 | 0.19 | 0.25 | 0.047 | 0.032 | 0.006 | 0.5 | |
| Sta-695 | 16 | 0.25 | 0.047 | 0.032 | 0.002 | 1 | |
| Sta-1595 | 6 | 0.25 | 0.047 | 0.19 | 0.004 | 0.5 | |
| Sta-1629 | 8 | 32 | 0.047 | 0.125 | 0.004 | 0.5 | |
| Sta-1671 | 8 | 12 | 0.047 | 0.094 | 0.004 | 0.75 | |
| Sta-1708 | 8 | 0.38 | 0.047 | 0.047 | 0.004 | 0.5 | |
| ST59 | P2 | 0.25 | 256 | 0.064 | 3 | 0.008 | 1 |
| P11 | 0.25 | 16 | 0.094 | 0.032 | 0.016 | 1.5 | |
| P16 | 0.25 | 0.38 | 0.032 | 0.064 | 0.008 | 1.5 | |
| P65 | 0.25 | 64 | 0.064 | 0.047 | 0.006 | 1 | |
| Sta-329 | 32 | 0.38 | 0.047 | 0.032 | 0.008 | 1.5 | |
| Sta-414 | 0.25 | 4 | 0.032 | 0.032 | 0.004 | 0.5 | |
| Sta-468 | 32 | 0.5 | 0.032 | 0.047 | 0.006 | 1.5 | |
| Sta-790 | 0.25 | 8 | 0.047 | 1.5 | 0.004 | 0.38 | |
| ST239 | P61 | 32 | 256 | 8 | 0.064 | 0.006 | 1.5 |
| Sta-271 | 32 | 256 | 8 | 0.047 | 0.004 | 1 | |
| Sta-297 | 32 | 256 | 8 | 0.032 | 0.004 | 1 | |
| Sta-311 | 32 | 256 | 12 | 0.032 | 0.004 | 1 | |
| Sta-314 | 32 | 256 | 6 | 0.032 | 0.004 | 0.75 | |
| Sta-373 | 32 | 256 | 4 | 2 | 0.004 | 1 | |
| Sta-390 | 32 | 256 | 32 | 0.047 | 0.004 | 1.5 | |
| Sta-436 | 32 | 256 | 4 | 0.094 | 0.004 | 1 | |
| Sta-635 | 32 | 256 | 12 | 0.19 | 0.006 | 1 | |
| Sta-1597 | 32 | 256 | 32 | 0.064 | 0.006 | 1.5 | |
| Sta-1730 | 32 | 256 | 32 | 0.064 | 0.006 | 1 | |
| ST5 | Sta-697 | 32 | 96 | 0.047 | 0.047 | 32 | 0.75 |
| Sta-1709 | 32 | 128 | 0.047 | 0.094 | 32 | 0.5 | |
| ST7 | P9 | 0.25 | 12 | 0.064 | 3 | 0.004 | 1 |
| ST45 | Sta-1628 | 12 | 0.38 | 0.047 | 0.19 | 0.004 | 0.38 |
| ST508 | Sta-516 | 0.125 | 0.25 | 0.047 | 0.047 | 0.006 | 0.38 |
| Sta-1411 | 0.125 | 0.19 | 0.047 | 0.125 | 0.006 | 0.75 | |
| ST1232 | Sta-1505 | 0.25 | 0.19 | 0.047 | 0.19 | 0.006 | 0.5 |
Abbreviations: MLST—multilocus sequence typing; MRSA—methicillin-resistant Staphylococcus aureus; MIC—minimum inhibitoryconcentration; ST—sequence type; TMP-SMX—trimethoprim-sulfamethoxazole.
Figure 1Biofilm formation of MRSA clinical isolates. The biofilm formation of MRSA isolates was investigated after 24 h incubation in a microtiter plate: (A) Comparison of biofilm formation capacities of MRSA from the skin and soft tissue infection (SSTI) (n = 22) and periprosthetic joint infection (PJIs) (n = 36). Each shape (● and ■) represents individual isolates, and bars indicate the means, * p < 0.05 are considered significant; (B) biofilm formation of PJIs-MRSA clinical isolates with different ST types. Each shape (●, ■, ▲, ▼, ◆, ○, □, and △) represents individual isolates categorized into different ST types, and bars indicate the means, * p < 0.05 is considered to be significant. In other ST strains, the shapes ▼, ◆, ○, □, and △ represents ST5, ST7, ST45, ST508, ST1232, respectively.
Figure 2Numbers of operations and admissions in PJIs. The medical record review and analysis showed that the number of surgical debridements and the number of hospital admissions were generally high for PJI patients with ST239 MRSA infection as compared with infections with the other MRSA genogroups. Data are expressed as means ± SD, * p < 0.05 is considered to be significant.
Figure 3The association of biomarkers of pre-operative status and MRSA strains: (A) C-reactive protein value (CRP); (B) white blood cell count (WBC); (C) erythrocyte sedimentation rate (ESR) were measured. Data are expressed as means ± SD, * p < 0.05 is considered to be significant.
Levels of biomarkers of pre-operation in PJIs.
| Variables | ST8 | ST59 | ST239 | ST5 | ST7 | ST45 | ST508 | ST1232 |
|---|---|---|---|---|---|---|---|---|
| CRP:mg/dL | 66.8 ± 57.56 | 184.29 ± 90.60 | 279.16 ± 109.53 | 160.3 ± 0 | 78.52 | 218.92 | 97.54 ± 135.18 | 14.84 |
| WBC:/μL | 9.79 ± 3.86 | 14.1 ± 4.02 | 18.49 ± 5.32 | 12.8 ± 0 | N.A | 13.4 ± 4.02 | 14.6 ± 8.49 | 10.1 |
| ESR:mm/hr | 78.29 ± 29.53 | 92.75 ± 45.83 | 95.33 ± 21.21 | 86 ± 0 | 140 | N.A | 15.15 ± 5.44 | 60 |
| Fever | 1/10 | 0/8 | 7/11 | 0/2 | 1/1 | 0/1 | 0/2 | 0/1 |
All data were presented as means ± SD (range). The average values of CRP, ESR, and WBC included all pre-operative data of each patient. Fever is defined as 37.5 degrees Celsius or above according to pre-operative records. Abbreviation: ST—sequence type; CRP—C-reactive protein; vWBC—white blood cell count; ESR—erythrocyte sedimentation rate; N.A.—not available, PJIs—periprosthetic joint infections.
Demographics of patients in MRSA induced PJIs.
| Characteristic | MRSA Isolates | |||
|---|---|---|---|---|
| ST8 ( | ST59 ( | ST239 ( | Others ( | |
| Sex | ||||
| Female | 2 (20%) | 4 (50%) | 7 (64%) | 3 (43%) |
| Male | 8 (80%) | 4 (50%) | 4 (36%) | 4 (57%) |
| Age (year) | ||||
| Mean ± SD | 62 ± 19 | 70 ± 17 | 56 ± 16 | 71 ± 17 |
| Range | 26–86 | 40–86 | 29–98 | 41–87 |
| Underlying diseases | ||||
| CHC | 4 (40%) | 2 (25%) | 9 (82%) | 2 (29%) |
| CKD | 0 | 0 | 1 (9%) | 2 (29%) |
| DM | 2 (20%) | 3 (38%) | 1 (9%) | 3 (43%) |
| Gout | 0 | 2 (25%) | 0 | 1 (14%) |
| Cancer | 0 | 0 | 2 (18%) | 0 |
Abbreviation: MRSA—methicillin-resistant Staphylococcus aureus; PJIs—periprosthetic joint infections; CHC—chronic hepatitis and cirrhosis; CKD—chronic kidney disease; DM—diabetes mellitus.
Figure 4The surgical site and annual trends of MRSA strains: (A) The percentage of the surgical sites; (B) yearly cases numbers of ST8, ST59, ST239, and other ST MRSA in PJI patients.